• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·PEHA.JK
Share

PT Phapros, Tbk Stocks

IDR 266Last Updated 07.08.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

IDR 13.20M

IDR 266
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 13:01

A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

08.08.2026 02:52

U.S. stocks posted their best weekly gain since mid-April. The S&P 500 hit a new record high.

08.08.2026 02:36

OpenAI has suspended development of a new AI model due to cybersecurity risks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026